PMV Pharmaceuticals stock (US7301281085): Q1 2026 results and rezatapopt orphan drug nod

PMV Pharmaceuticals (Nasdaq: PMVP) released first quarter 2026 financial results and corporate highlights on May 12, 2026, reporting a net loss of $18 million, or $(0.34) per share, roughly flat from $17.4 million last year, according to BioSpace as of 05/12/2026. Key advances include FDA Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer and New England Journal of Medicine publication of first-in-human data showing selective p53 reactivation in solid tumors. The company plans an NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

PMV Pharmaceuticals: core business model

PMV Pharmaceuticals is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, which occur in approximately 50% of cancers. The company's lead candidate, rezatapopt (formerly PC14586), is a tumor-agnostic therapy designed to correct mutant p53 Y220C proteins and restore wild-type p53 function, according to the company's Q1 2026 press release via BioSpace as of 05/12/2026. PMV Pharma, headquartered in Princeton, New Jersey, went public on Nasdaq under ticker PMVP in 2020.

Rezatapopt has received FDA Fast Track designation for locally advanced or metastatic solid tumors with p53 Y220C mutation and Orphan Drug Designation for ovarian, fallopian tube, and primary peritoneal cancers with the same mutation. Enrollment continues in the Phase 2 monotherapy portion of the PYNNACLE clinical trial.

Main revenue and product drivers for PMV Pharmaceuticals

PMV Pharmaceuticals remains pre-revenue, with development funded by cash reserves. As of March 31, 2026, the company held $93.5 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q2 2027, per the Q1 financial results published May 12, 2026, via GlobeNewswire/BioSpace as of 05/12/2026. The primary value driver is rezatapopt's potential in p53-mutated cancers, particularly ovarian cancer where an NDA is targeted for Q1 2027.

Recent NEJM publication highlighted first-in-human data demonstrating rezatapopt's selective reactivation of mutant p53 in advanced solid tumors, bolstering the path toward regulatory approval.

Industry trends and competitive position

The precision oncology market, valued at billions with strong US exposure, benefits companies like PMV Pharmaceuticals targeting specific mutations like p53 Y220C. TP53 mutations drive a significant portion of solid tumors, creating demand for targeted therapies amid a shift from broad chemotherapies.

Why PMV Pharmaceuticals matters for US investors

Listed on Nasdaq, PMV Pharmaceuticals offers US investors direct access to innovative biotech plays in oncology, a sector critical to the US healthcare economy. FDA designations signal regulatory momentum relevant to American markets.

Conclusion

PMV Pharmaceuticals' Q1 2026 update underscores pipeline progress with rezatapopt, including FDA Orphan Drug Designation, NEJM data publication, and an NDA timeline into 2027, alongside a stable cash position. These developments position the company amid key milestones in precision oncology. Investors track clinical and regulatory catalysts in this Nasdaq-listed biotech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.